Cannabis Law Report

AUGUST 7, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

SEPTEMBER 21, 2021

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Patients 94

Patients Research and Development Sleep Clinical Trials 94

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Canna Law Blog

NOVEMBER 10, 2020

We discussed how licensed facilities won’t be up and running for a few more years, and how, in the meantime, people will have to make do with general decriminalization under Measure 109 and maybe, in certain cases, reliance on Right to Try access. It’s quite restrictive. Or, it could be because FDA is sort of a drag about everything.

Therapy 78

Therapy Clinical Trials Decriminalization Patients 78

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. The report further breaks down use by specific cultivars.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. We are pioneering a new kind of pharmaceutical company that prioritizes public benefit and is committed to sustainability, accountability, and transparency.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

SEPTEMBER 12, 2022

Our mushrooms are some of the most tested products on the planet as we cross the lines between Pharmaceutical, Agriculture, Botanical, and Food testing quality assays,” said Optimi Chief Science Officer, Justin Kirkland. To access a complete photo gallery of this historic grow, please click here. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

MARCH 29, 2022

Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. Prior to his work at Moderna, Mullette developed broad pharmaceutical expertise with Sanofi in a variety of management roles in the U.S., Mullette joins MAPS PBC after more than 20 years in the pharmaceutical industry. He holds a B.S.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

MMJ Recs

NOVEMBER 20, 2023

These compounds may help reduce symptoms and improve the quality of life for patients. Cannabis Research and Patient Outcomes The scientific exploration of cannabinoids and their therapeutic effects has opened the door to numerous research initiatives. The outcomes of these studies have had a profound impact on patient care.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. Executive Summary. Minimum Requirements.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

The Cannigma

APRIL 12, 2023

Cannabis is often reported to help people reduce the number of pharmaceuticals they’re taking, and this trend continues in this study. Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. Has CBN been proven to help with sleep? This CBN study is one such example.

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. Doug Drysdale is an experienced director, having been CEO and chairman of the board of Nasdaq-listed companies and pharmaceutical firms.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Key Responsibilities. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

DECEMBER 18, 2019

…MGC Pharmaceuticals has achieved yet another significant milestone with the bio-pharma company this week surpassing more than 1,800 prescribed products of its medicinal cannabis-based pharmaceutical products in Australia, UK, Brazil and Ireland. The West Australian reports. Source: [link].

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

Cannabis Law Report

SEPTEMBER 20, 2021

provides Heritage and subsidiary Opticann the benefits of offering patients access to safe, convenient, and effective CB4 products developed on trusted technology platforms. The products leverage pharmaceutical technology to maximize performance and safety. TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

OCTOBER 10, 2021

As a think tank we develop new ideas and concepts for providing medical cannabis to patients both in Germany and Europe. Cantourage is an innovative company ensuring that patients are able to access the newest medicinal products based on cannabis.

Clinical Trials 52

Clinical Trials Therapy Medicine Policy 52

Cannabis Law Report

FEBRUARY 9, 2022

The application includes claims that Vocan’s technology will enable the production of cGMP API grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law, consumers, and patients. About Core One Labs Inc.

Research and Development 52

Research and Development Clinical Trials Treatment Patients 52

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Accessibility.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

LifeCannMD

FEBRUARY 1, 2022

As a result, these patients often experience high levels of stress, anxiety, and depression. The symptoms of OCD are often separated into obsession and compulsion, but a patient can be diagnosed for exhibiting severe symptoms in either of these categories: Obsessive. Medical Marijuana for a Patient with OCD. Restlessness.

Marijuana 98

Marijuana Clinical Trials Patients Therapy 98

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. A doctor who applies to the TGA on behalf of a patient must provide a clinical justification.

Legalization 52

Legalization Access Medicine Clinical Trials 52

SpeedWeed

AUGUST 16, 2021

Oxford-based startup Beckley Psytech in the United Kingdom announced August 15 that it raised $80 million to ramp up clinical trials and research using a pharmaceutical formulation of ??5-MeO-DMT The post Psychedelic Toad Venom Clinical Research Boosted by $80M in Funding appeared first on SpeedWeed.

Research and Development 52

Research and Development Clinical Trials Treatment Conditions 52

Veriheal

OCTOBER 13, 2020

Elevated levels of stress can even land these individuals in more discomfort, with IBD patients risking hospitalization due to inflammation. Factors such as diet and stress are known to aggravate IBD patients, but they do not cause it. . What is IBS? What is the Difference Between IBD and IBS?

Digestion 120

Digestion Treatment Conditions Research and Development 120

Cannabis Law Report

JANUARY 19, 2022

GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products. “A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. Epidiolex contains less than 0.1

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

DECEMBER 14, 2019

The uptick has been represented in the patient count, as well. Although we note the early stage of the sector in Australia and the associated volatility of a nascent industry, over the same period patient numbers domestically have continued to soar,” Bell and Smith wrote in their note. Learn to profit from cannabis companies.

Pharmaceutical 98

Pharmaceutical Patients Clinical Trials Hemp 98

Cannabis Law Report

DECEMBER 17, 2021

deletion syndrome patient pool and forecasted trend for each seven major countries. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken. deletion syndrome is often underdiagnosed and misdiagnosed, as the symptoms vary from patient to patient. Emerging Drugs.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Therapy 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products. ‘1948 Law No.

Legalization 58

Legalization Marijuana Clinical Trials Seed-To-Sale 58

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Program between St. Bonaventure University and George Washington University School of Medicine. . School: University of Maryland.

Research and Development 117

Research and Development Education Agriculture Patients 117